Vasomotor Symptoms in Menopause: Evidence-Based Approaches for Hot Flashes and Night Sweats

The Hypothalamic Thermostat: Why Hot Flashes Happen

Vasomotor symptoms—commonly referred to as hot flashes and night sweats—are the hallmark physical manifestation of the menopausal transition, affecting approximately 75% to 80% of women worldwide. While often trivialized in popular culture, severe vasomotor episodes can profoundly disrupt sleep quality, workplace productivity, and overall psychological wellbeing.

To address hot flashes effectively, it is helpful to understand the underlying neurology.

The Narrowed Thermoneutral Zone

Body temperature is regulated by the preoptic area of the hypothalamus. In healthy premenopausal states, the hypothalamus maintains a generous "thermoneutral zone"—a temperature window within which core body temperature can fluctuate without triggering sweating or shivering.

During the menopausal transition, declining and fluctuating estrogen levels cause hypertrophy of specialized hypothalamic neurons known as KNDy neurons (kisspeptin, neurokinin B, and dynorphin). This neurochemical shift triggers inappropriate release of norepinephrine and neurokinin B, severely narrowing the thermoneutral zone.

As a result, an infinitesimal change in ambient temperature (such as walking into a warm room or drinking hot tea) is perceived by the brain as a life-threatening thermal surge. The hypothalamus initiates an aggressive heat dissipation response: rapid peripheral vasodilation, flushing, tachycardia, and profuse perspiration followed by chills.

Evidence-Based Clinical Management

1. Non-Pharmacological Strategies

• Thermal Environment Optimization: Dressing in moisture-wicking natural fibers (such as bamboo or cotton), sleeping in cool rooms (65°F / 18°C), and utilizing bedside fans.
• Cognitive Behavioral Therapy (CBT): Recommended by The Menopause Society for reducing the subjective distress and perceived frequency of hot flashes.
• Trigger Management: Identifying personal triggers such as alcohol, spicy foods, caffeine, and cigarette smoke.

2. Medical Treatments

For women experiencing moderate to severe symptoms, clinical guidelines emphasize individualized medical care:

• Hormone Replacement Therapy (HRT): Systemic estrogen (combined with a progestogen for women with an intact uterus to prevent endometrial hyperplasia) remains the gold standard for vasomotor relief in eligible women within 10 years of menopause or under age 60.
• Non-Hormonal Neurokinin 3 (NK3) Receptor Antagonists: Newer targeted oral medications (such as fezolinetant) directly block neurokinin B signaling on KNDy neurons without hormonal exposure.
• SSRIs and SNRIs: Medications such as paroxetine and venlafaxine offer proven clinical alternatives for women who cannot take estrogen.